Valye reports for unlimited access

Keen Vision Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) incorporated in the British Virgin Islands in 2021. It completed its IPO in July 2023, raising net proceeds of approximately $151 million, which are held in a trust account invested primarily in U.S. Treasury securities and money market funds. The company’s management team has extensive experience in private equity, de-SPAC transactions, and corporate finance, focusing on identifying a growth-oriented target in the biotech, consumer goods, or agriculture sectors with strong ESG considerations. KVAC has entered into a letter of intent with Medera and its subsidiary Novoheart for a potential business combination centered on pre-clinical human disease modeling and drug discovery. The company’s financial position as of December 31, 2025, shows limited operating cash but significant trust account assets. The company’s acquisition strategy emphasizes rigorous due diligence, operational improvements, and leveraging capital markets access post-combination.

ServiceTitan, Inc. provides a comprehensive cloud-based software platform designed specifically for the trades industry, which encompasses field service activities for residential and commercial infrastructure. The platform supports critical business functions including customer relationship management, field service management, enterprise resource planning, human capital management, and financial technology services. ServiceTitan's software is deeply embedded in its customers' operations, enabling automation and data-driven insights to improve business outcomes. The company generates revenue primarily through subscription fees and usage-based fees linked to the size and activity of its customers' businesses. ServiceTitan has experienced rapid growth in revenue and employee headcount, with a focus on expanding product offerings, including AI-powered features, and geographic reach. The company operates internationally and maintains strong liquidity to support ongoing investments and operations [S1].

JBS N.V. is the world's largest protein company by net revenue, operating a global platform that prepares and delivers a wide range of protein products including beef, poultry, pork, lamb, fish, and eggs. The company has significant processing capacities across multiple continents, including the largest global capacities in beef and poultry production. Its products are marketed under numerous well-known brands across North America, Brazil, Australia, and Europe. JBS operates through seven reportable segments and serves over 330,000 customers worldwide. The company generates the majority of its revenue domestically in countries where it operates facilities, with a substantial portion from exports, particularly to Asia, Africa, and the Middle East. JBS has made strategic investments to expand its production capabilities and diversify geographically, including new facilities in the US and a multiprotein platform in Oman. The company maintains a strong liquidity position and a well-staggered debt maturity profile, supported by cash flows from operations and credit facilities.

Polyrizon Ltd. develops innovative medical device hydrogels delivered as nasal sprays that form a physical barrier in the nasal cavity to block viruses and allergens. The company’s proprietary C&C technology acts as a "biological mask" by creating a thin hydrogel shield, while the T&T platform focuses on sustained intranasal delivery of active pharmaceutical ingredients (APIs). The C&C product candidates, including NASARIX™ (PL-14) for nasal allergies and PL-16 for influenza, are positioned as Class II medical devices regulated by the FDA, with NASARIX™ pursuing 510(k) clearance and PL-16 pursuing De Novo classification. The T&T platform targets delivery of corticosteroids, benzodiazepines, and naloxone, with feasibility studies underway and clinical trials planned. Polyrizon operates primarily in Israel and holds an exclusive license from SciSparc Ltd. for the SCI-160 platform related to pain treatment. The company reported a net loss for the fiscal year ending 2025 and maintains a strong liquidity position. Recent news highlights include strategic acquisition plans and clinical development milestones.

Marex Group plc is a global financial services firm providing market access, infrastructure, and liquidity services across commodity and financial markets. Incorporated in England and Wales, Marex operates through four interconnected business segments: Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions. Clearing connects clients to over 60 exchanges worldwide, acting as principal and generating commission revenue. Agency and Execution offers liquidity primarily in energy and financial securities markets, while Market Making provides direct market pricing across multiple asset classes with revenue from bid-ask spreads. Hedging and Investment Solutions delivers bespoke hedging products to manage commodity and currency risks. The company serves over 3,400 active clients including commodity producers, traders, banks, and asset managers, supported by more than 3,000 employees globally. Marex has expanded through acquisitions such as Valcourt SA and Webb Traders to enhance its fixed income and equity derivatives offerings. The company’s financial performance is influenced by commodity price volatility, economic conditions, geopolitical events, and interest rate changes. Marex maintains regulatory capital and liquidity requirements under UK IFPR and manages risks related to market volatility, regulatory compliance, and acquisition integration.

COSCIENS Biopharma Inc. develops and commercializes natural active ingredients primarily derived from oats, targeting personal care, cosmetic, human, and animal health markets. The company uses proprietary technologies such as Ethanol Fractionation Processes and licensed PGX Technology to produce bioactive ingredients. The PGX Technology enables advanced processing of biopolymers into novel materials with applications across functional foods, nutraceuticals, cosmeceuticals, and pharmaceuticals. COSCIENS historically operated a biopharmaceutical segment focused on Macrilen®, an FDA and EMA approved diagnostic test, but this segment is being wound down due to clinical setbacks and insolvency of German subsidiaries. The company sells mainly through distribution networks, minimizing direct sales and marketing expenses. COSCIENS is implementing cost-saving strategies including delisting from Nasdaq and plans to suspend SEC reporting obligations. Financially, the company reported $7.5 million revenue and a net loss of $10.4 million for 2025, with cash reserves supporting operations into 2027 [S1][N1][N2][N3].

Texas Community Bancshares, Inc. is a Maryland-based bank holding company for Broadstreet Bank, SSB, a Texas-chartered savings bank headquartered in Mineola, Texas. The company provides a range of banking services including residential and commercial real estate loans, construction loans, municipality loans, commercial and consumer loans, and invests in various securities. Its primary market area covers several counties in Texas including Mineola and the Dallas-Fort Worth Metroplex. The company operates under regulatory oversight from the Federal Reserve Board, Texas Department of Savings and Mortgage Lending, and the FDIC. It offers deposit products such as checking, savings, money market, and certificates of deposit. The company faces competition from a variety of financial institutions in its local market.

MaxCyte, Inc. operates as a commercial cell engineering company focused on enabling platform technologies to advance discovery, development, and commercialization of next-generation cell therapeutics, including cell and gene therapies. The company’s core technology is its proprietary Flow Electroporation® platform, which facilitates the delivery of molecules such as DNA, mRNA, siRNA, and proteins into a wide variety of eukaryotic cells with high efficiency, viability, and reproducibility. The ExPERT platform comprises five instruments (DTx, ATx, STx, GTx, VLx) and a portfolio of proprietary processing assemblies (PAs) and consumables, designed to support scalable cell engineering from research through cGMP manufacturing. MaxCyte’s technology is used by leading biopharmaceutical companies, academic institutions, and government agencies, including the NIH. The company’s business model includes sales of instruments, disposables, consumables, annual license fees, and milestone and sales-based payments under strategic partner license agreements. MaxCyte acquired SeQure Dx in January 2025 to expand its gene editing assessment services. The company maintains a robust intellectual property portfolio and quality management system compliant with ISO 9001:2015 standards. As of December 31, 2025, MaxCyte had strong liquidity with $20.07 million in cash and $82.98 million in short-term investments, a current ratio of 8.3, and reported $33.03 million in revenue and a net loss of $44.63 million for the fiscal year 2025.

BeyondSpring Inc. develops innovative cancer therapies with a focus on its lead drug candidate Plinabulin, which is being tested in multiple cancer indications including metastatic NSCLC. The company also operates a targeted protein degradation (TPD) platform through its subsidiary SEED Therapeutics, which it has been divesting since late 2024. BeyondSpring’s business model includes clinical development, strategic collaborations, and equity investments in subsidiaries. The company’s financials show ongoing research and development expenses, moderate liquidity, and net losses consistent with a clinical-stage biopharmaceutical company. Its operations span the U.S. and China, with offices in New Jersey and Beijing/Dalian. BeyondSpring’s recent news and SEC filings provide updates on clinical progress, financial transactions, and corporate strategy.

Cognyte Software Ltd. was spun off from Verint in 2021 and focuses on providing cybersecurity software solutions, particularly in investigative analytics and cyber intelligence. The company generates revenue through software sales, software services including support and SaaS subscriptions, and professional services such as deployment and consulting. Cognyte operates globally with significant revenue contributions from EMEA, Americas, and APAC regions. The company invests heavily in research and development and maintains a strong liquidity position. Management and board members have extensive experience in cybersecurity and technology sectors. Cognyte has engaged in strategic acquisitions and share repurchase programs to support growth and shareholder value.

Foresight Autonomous Holdings Ltd. develops advanced stereoscopic 3D perception systems and cellular-based vehicle-to-everything (V2X) safety applications. Its technology mimics human depth perception using synchronized cameras to create dense 3D point clouds, applicable across automotive, defense, agriculture, industrial equipment, urban rail, and unmanned aerial vehicles. The company operates through subsidiaries including Foresight Automotive and Eye-Net Mobile, the latter focusing on AI-driven V2X collision prevention solutions delivering real-time alerts via smartphones and smart devices. Foresight's products address challenges in autonomous driving such as obstacle detection in diverse and adverse conditions, supporting higher levels of vehicle automation. The company has established strategic partnerships and joint ventures globally to advance commercialization and technology deployment in key markets.

Brenmiller Energy Ltd. develops and markets thermal energy storage systems using its patented bGen™ technology, which stores heat in crushed rocks at high temperatures for industrial and power applications. The TES systems provide flexible, dispatchable thermal energy to support electrification and decarbonization efforts, integrating renewable energy and reducing carbon emissions. The company offers modular, passive TES solutions with low maintenance and long lifetimes. Its business model includes direct equipment sales with after-sales services and Energy as a Service contracts where Brenmiller owns and operates TES systems at customer sites. In 2026, Brenmiller announced the BNRG360 integrated energy platform to bundle TES with solar photovoltaic and battery storage under long-term contracts. The company manufactures TES components in a facility in Dimona, Israel, with a current capacity of 1 GWh and potential expansion to 4 GWh. Brenmiller targets markets in the US, Europe, and Israel, with a growing pipeline of commercial projects and partnerships. The company has reported operating losses and negative cash flows since inception and is pursuing additional financing to support its commercialization efforts [S1][S2].

Hashdex Nasdaq CME Crypto Index ETF is a Delaware-registered exchange-traded fund listed on Nasdaq under the ticker NCIQ. The fund tracks the Nasdaq CME Crypto Settlement Price Index, having transitioned from the Nasdaq Crypto US Settlement Price Index effective January 20, 2026. The ETF operates under a Trust structure with a Sponsor and Trustee, and is classified as an emerging growth company. The fund's business model centers on providing investors exposure to a crypto asset index through an ETF vehicle. Operationally, the Trust has implemented infrastructure agreements to support staking activities and has enabled in-kind creation and redemption processes for authorized participants. Financial disclosures indicate a net loss for the fiscal year ending December 31, 2025, with limited other financial metrics disclosed.

Oak Valley Bancorp is a regional bank headquartered in Oakdale, California, serving primarily the Central California region including the Central Valley and foothill counties. The bank operates nineteen full-service branches and offers a comprehensive suite of banking products such as deposit accounts, commercial and consumer loans, and digital banking services. The company’s loan portfolio is predominantly real estate-related, reflecting its focus on the local real estate market. The bank competes with major national and regional banks as well as other financial institutions in its service area. Management emphasizes personalized service and local marketing to maintain competitive positioning. The company’s financial results for the fiscal year ended December 31, 2025, include net income of $23.9 million and basic EPS of $2.90, supported by asset growth and stable deposit funding.

Chenghe Acquisition III Co. is a blank check company incorporated in the Cayman Islands in June 2024. Its business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more target businesses. The company completed its Initial Public Offering in September 2025, issuing units at $10.00 each and raising gross proceeds of approximately $126.5 million, plus $4.08 million from private placement units sold to co-sponsors and underwriters. The proceeds are held in a Trust Account to be used for the initial business combination. The company has no operating revenues or business operations to date and generates income primarily from interest earned on Trust Account funds. It incurs costs related to being a public company and pursuing acquisition plans. The company’s shares and warrants trade on Nasdaq under the symbols CHEC and CHECW respectively after separation of units. The company’s ability to continue operations depends on completing an initial business combination within the prescribed timeframe, or it will be forced to liquidate.

UTG INC is a Delaware-incorporated insurance holding company headquartered in Stanford, Kentucky. Its main operating subsidiary, Universal Guaranty Life Insurance Company (UG), conducts individual life insurance business across 37 states. UTG itself has no significant operations and depends on dividends and fees from UG. The company maintains a philanthropic focus and is majority-owned by CEO Jesse T. Correll. UG's insurance products include fixed premium whole life policies and annuities, though new policy sales are currently limited. UTG also provides third-party administrative services, which contribute minimally to revenue. The company holds investments concentrated in oil and gas and related real estate royalties. UTG operates under extensive state insurance regulations and maintains adequate capitalization. The company has a stock repurchase program and reported $42.3 million in revenue and $17.1 million in net income for fiscal 2025.

Juniata Valley Financial Corp is a one-bank holding company with a long history dating back to 1867 through its bank charter. It operates primarily in central and northern Pennsylvania, serving local communities with retail and commercial banking services. The company’s offerings include personal and business checking and savings accounts, loans (including mortgages and commercial loans), debit cards, certificates of deposit, and wealth management and trust services. The bank’s deposit base is primarily local, and it competes with a range of financial institutions including community banks, regional and national banks, credit unions, and fintech providers. The company’s lending policies focus on sound underwriting and serving small to mid-sized businesses within its market area. Juniata Valley Financial maintains a stable deposit base and a diversified loan portfolio with detailed credit quality monitoring.

GENESCO INC is a multi-segment footwear and apparel company with key business units including Journeys Group, Schuh Group, Johnston & Murphy Group, and Genesco Brands Group. The company’s revenue streams derive from retail stores, e-commerce, wholesale, and branded product sales. Recent financial disclosures indicate modest growth in net sales and improvements in certain segments, notably Journeys Group, while others face challenges due to market conditions and tariff impacts. The company maintains liquidity through cash reserves and credit facilities, with ongoing capital investments focused on store renovations and expansions.

byNordic Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in Delaware, formed to effect an initial business combination. The company targets technology growth companies primarily in northern Europe, including Nordic and Scandinavian countries, the Baltic states, UK, Ireland, Germany, France, and Benelux countries. The management team has extensive experience in various technology sectors such as FinTech, digital infrastructure, software including AI, health technology, sustainability/climate technology, transportation technology, and industrial technology. The company completed its initial public offering in February 2022, raising gross proceeds of $150 million plus additional private placements, with funds held in a trust account. The company has extended its deadline to complete an initial business combination multiple times, currently until at least April 12, 2026. It has no operating business or revenue and will not engage in operations until the initial business combination is consummated. The company’s acquisition criteria focus on technology companies with enterprise valuations below $750 million, primarily between $150 million and $750 million, with differentiated products or services addressing unmet needs and growth opportunities. The company may use cash, debt, equity securities, or combinations thereof to effectuate the initial business combination. Officers and directors may have conflicts of interest due to ownership stakes and other fiduciary obligations, but independent opinions are sought for affiliated transactions. Public stockholders have redemption rights in connection with the initial business combination or if the combination is not completed by the deadline.

Galaxy Enterprises Inc. was incorporated in March 2021 and intends to provide real estate management and consulting services primarily in the Las Vegas, Nevada area. The company plans to offer property management services such as tenant screening, lease administration, rent collection, maintenance oversight, and financial reporting. Consulting services will include market analysis, property valuation, feasibility studies, strategic planning, and capital management advice. Revenue will be generated through monthly fees based on rental income percentages and hourly or negotiated consulting fees. The company has not yet commenced operations and currently has no employees other than its sole officer and director. Marketing efforts will leverage local real estate relationships and digital media platforms. The company operates in a highly competitive and fragmented market with established national and local competitors. It is subject to Nevada state licensing requirements for real estate brokers and property managers. Population growth and construction activity in the region are cited as factors increasing demand for its services [S1][S2].

Intrusion Inc., headquartered in Plano, Texas, is a cybersecurity firm offering proprietary threat intelligence and network security solutions. Its core product, INTRUSION Shield, is a Zero Trust SaaS platform that analyzes network traffic to block malicious connections, with variants for on-premise, cloud, and endpoint protection. The company also offers TraceCop, a comprehensive IP intelligence big data tool, and Savant, a network monitoring and forensic analysis solution used by U.S. government agencies. Intrusion's revenues are predominantly derived from U.S. government customers, accounting for over 94% of 2025 revenues. The company sells through direct sales and channel partners, including resellers and integrators. Intrusion reported $7.1 million in revenues and a net loss of $9.1 million for fiscal 2025, with liquidity ratios indicating moderate short-term financial stability. The company faces substantial doubt about its ability to continue as a going concern without additional financing. Competition is intense in the cybersecurity market, with principal competitors including Darktrace, Trellix, and Recorded Future, though TraceCop currently has few direct competitors due to its extensive historical data.

Spectral AI, Inc. is a medical technology company specializing in AI-enabled predictive diagnostics for burn wounds through its DeepView System. The system integrates proprietary multispectral imaging hardware and AI algorithms to classify wound tissue and predict healing outcomes at the initial patient presentation. The technology is designed to assist healthcare professionals in making timely and accurate treatment decisions, potentially reducing hospital stays and associated costs. The company’s business model includes a SaaS software licensing component and capital sales of imaging devices. Spectral AI has received substantial U.S. government funding, primarily from BARDA, supporting clinical validation, regulatory submissions, and product development. The company has achieved UKCA marking and is pursuing FDA De Novo clearance. It also develops additional products such as a handheld DeepView SnapShot M device and 3D wound measurement technology. The company employs a growing workforce and plans to expand commercial operations in the U.S. and UK markets, targeting burn centers, trauma centers, and emergency rooms. Key risks include regulatory uncertainties, supplier dependencies, capital requirements, and competition from other wound imaging technologies.

UiPath Inc is a technology company specializing in software infrastructure, providing an automation platform that enables enterprises to adopt agentic automation and AI-driven process improvements. The platform supports flexible deployment options including on-premises and cloud-based SaaS offerings. Revenue streams include software licenses, subscription services (maintenance, support, SaaS), and professional services such as deployment and training. The company emphasizes growth through expanding its customer base, increasing sales to existing customers, and leveraging channel partners and strategic alliances. UiPath invests heavily in research and development to maintain innovation leadership and competitive advantage in the automation and AI market. The company operates globally and faces macroeconomic and geopolitical risks that may impact demand and financial results. Seasonality affects sales cycles, with higher license agreements and renewals typically in the second half of the fiscal year. UiPath completed workforce restructurings in recent years to optimize operations and focus investments on AI and innovation.

Nexalin Technology, Inc. is a Houston-based medical device company focused on developing bioelectronic neurostimulation products to address mental health conditions. Its original Gen-1 device uses cranial electrotherapy stimulation at 4 milliamps and is FDA Class II for anxiety and insomnia treatment but is no longer actively marketed for new sales in the U.S. The company is developing next-generation devices, Gen-2 SYNC and Gen-3 HALO, which emit a proprietary 15 milliamp waveform designed for deeper brain stimulation without discomfort or side effects. These devices are undergoing FDA Q-submission and pre-submission processes, with clinical trials planned or underway in the U.S. and internationally. Nexalin is also building a virtual clinic platform to enable tele-psychiatry diagnosis and remote patient monitoring. The company holds regulatory approvals in China, Brazil, and Oman and has a joint venture for commercialization in China. Manufacturing is outsourced to U.S. contractors under FDA quality standards. Nexalin holds multiple patents protecting its technology and has a Military & Government Advisory Board to support deployment in federal agencies.

Social Commerce Partners Corporation is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on August 11, 2025. The company was formed to identify and complete a merger, share exchange, asset acquisition, or similar business combination with one or more target businesses, with an initial focus on the social commerce (direct selling) industry. The company completed its initial public offering on December 24, 2025, issuing 10 million units at $10.00 per unit, raising gross proceeds of $100 million, which were placed in a trust account invested in U.S. government treasury obligations or money market funds. The company has not yet selected any business combination target and has not engaged in substantive discussions with any potential targets. It has a 24-month window from the IPO closing to complete a business combination or else must redeem public shares. The company has no operating revenues and reported a net loss of $583,044 for the period from inception through December 31, 2025. It maintains a strong liquidity position with a current ratio of 7.23 as of December 31, 2025, and has contractual obligations including monthly payments for office space and administrative support. The company is classified as an emerging growth company and a smaller reporting company under SEC rules, with reduced disclosure requirements.

CoJax Oil & Gas Corp is an oil and gas company incorporated in Virginia, United States. It is classified as a smaller reporting company under SEC rules, which reduces its disclosure obligations. The company reported revenues under $1 million and a net loss exceeding $1 million for the fiscal year ending December 31, 2025. Liquidity metrics indicate significant short-term financial constraints, with current liabilities substantially exceeding current assets. The company filed a corporate presentation in mid-2025 outlining strategic developments, but detailed operational or product information is not publicly disclosed in SEC filings or news sources.

Range Capital Acquisition Corp II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on May 22, 2025. The company completed its IPO on October 6, 2025, raising gross proceeds of $230 million through the sale of 23 million units, each consisting of one Class A ordinary share and one-half of a redeemable warrant. Concurrently, it completed a private placement of 660,000 units, generating $6.6 million. The net proceeds from these offerings were placed in a Trust Account to be used primarily for completing a business combination with one or more target businesses. The company has not commenced operations or generated revenues and currently earns interest income on the Trust Account investments. The board of directors includes experienced individuals with backgrounds in investment management and SPACs. The company’s financial statements are prepared under US GAAP and audited by CBIZ CPAs P.C. The company maintains a strong liquidity position with cash and current assets exceeding current liabilities by a wide margin as of December 31, 2025.

Everpure, Inc. provides an integrated storage and data management platform known as the Everpure Platform, which virtualizes data across on-premises, hybrid, public cloud, and edge environments into a unified storage layer with consistent control and automation. The company addresses four major market trends: the shift to all-flash technology, growth of cloud-native applications, demand for storage-as-a-service, and increasing AI-driven data storage needs. Its six strategic growth pillars include expanding all-flash use cases, hybrid cloud data services, subscription service growth, integrated data management, dataset management across hybrid/multi-cloud, and AI portfolio expansion for GPU and HPC environments. Everpure's product portfolio includes FlashArray and FlashBlade systems powered by Purity software and DirectFlash hardware. The company serves over 14,500 customers globally, including 64% of Fortune 500 companies, and sells through direct and channel partners. It faces competition from established storage vendors and cloud providers and manages supply chain and operational risks through contract manufacturers and supplier relationships.

USBC, Inc. is focused on delivering a tokenized bank deposit product that leverages blockchain technology to provide retail customers worldwide access to U.S. dollar deposit accounts. The company is in the early stages of product delivery, currently conducting an internal pilot to test technical readiness. Strategic partnerships with Uphold HQ Inc. and Vast Bank, N.A. form the foundation of its tokenized deposit network, with exclusivity agreements in place for market making and exchange services. The company has not reported revenue recently and is operating at a net loss, supported by liquidity from cash and current assets.

Nasus Pharma Ltd, incorporated in Israel in 2019, is a clinical-stage specialty pharmaceutical company focused on developing innovative intranasal powder-based drug delivery products for emergency medical conditions such as anaphylaxis and opioid overdose. The company's proprietary Powder-Based Inhalation (PBI) technology aims to provide rapid and efficient drug absorption through the nasal cavity, potentially offering advantages over liquid nasal solutions. Nasus Pharma's lead product candidate, NS002, is an intranasal epinephrine powder designed to treat anaphylaxis, with clinical trials demonstrating faster and higher peak plasma epinephrine levels compared to intramuscular injections like EpiPen. The company has conducted multiple Phase 2 studies and plans to initiate a pivotal Phase 3 trial in late 2026. Nasus Pharma has paused development of NS001, an intranasal naloxone product, and is seeking partnerships for its further development. The company operates as a virtual entity with collaborations for manufacturing and device development, including agreements with Aptar. Nasus Pharma is publicly listed on the NYSE American under the ticker NSRX and has completed a $15 million private placement in early 2026. The company reported $1.235 billion in revenue and a net loss of $5.856 million for the fiscal year ended December 31, 2025, with liquidity ratios indicating a current ratio of 2.24 and a cash ratio of 0.57. Nasus Pharma faces competition from established intranasal emergency drug products and generics and is pursuing partnerships to accelerate development and commercialization of its pipeline.

Paysign, Inc. is a vertically integrated payment processor and prepaid card program manager that provides prepaid card products and processing services to corporate, consumer, and government entities. The company’s payment solutions are designed to increase customer loyalty, improve patient adherence, reduce administrative costs, and streamline operations. Paysign’s product suite includes corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, pharmaceutical payment assistance, demand deposit accounts, and software solutions for blood and plasma collection organizations. The company’s cards are issued through bank partners and accepted on major payment networks. Paysign also offers a cloud-based technology platform for blood and plasma collection organizations under the Apherion™ brand. The company operates a bilingual, 24/7 in-house customer service center and employs a scalable, secure technology platform with cloud hosting and data analytics capabilities. Paysign competes in a fragmented market with a focus on direct marketing and strategic partnerships. As of December 31, 2025, Paysign managed approximately 670 card programs with about 8.4 million cardholders.

QT Imaging Holdings, Inc. develops and commercializes innovative breast imaging systems based on low-energy transmitted sound technology. Founded in 2012 and headquartered in Novato, California, the company aims to improve breast cancer screening and diagnostics by providing high-resolution, 3D volumetric images without ionizing radiation or breast compression. Its flagship product, the Breast Acoustic CT scanner, has received FDA 510(k) clearances, including enhancements for improved imaging coverage. The company is transitioning from a hardware manufacturer to a precision imaging platform by integrating cloud-based AI and machine learning capabilities through a SaaS model. QT Imaging targets intermediate and high-risk women, especially those with dense breast tissue, addressing limitations of current imaging modalities. Manufacturing is conducted internally and via contract manufacturing partnerships. The company has established strategic distribution agreements in the Gulf Cooperation Council region and plans further international expansion. Financially, QT Imaging reported a net loss of $21.1 million for 2025, with no revenue reported for 2023, and maintains liquidity with $10.4 million in cash and equivalents as of year-end 2025.

Enlivex Ltd. is a clinical-stage biotechnology company specializing in quality longevity therapies through macrophage reprogramming immunotherapy. Its lead product candidate, Allocetra™, is based on licensed apoptotic cell technology and is being developed primarily for inflammatory diseases such as osteoarthritis. The company holds a broad portfolio of patents and pending applications worldwide to protect its technology. Manufacturing of Allocetra™ occurs at a cGMP-certified facility in Ness Ziona, Israel, producing a frozen formulation to support clinical trials. Enlivex outsources clinical trial activities to CROs and currently does not have internal sales or marketing capabilities, intending to seek partnerships for commercialization. Financially, the company reported net income and strong liquidity as of the end of 2025, supported by recent capital raises. The company operates through subsidiaries in Israel, the US, and Poland.

Chewy, Inc. operates as a preeminent online retailer of pet products, supplies, and prescriptions, serving customers primarily in the U.S. and Canada through its websites and mobile applications. The company offers approximately 190,000 products from about 4,000 trusted brands, including its own private labels. Chewy emphasizes customer service, competitive pricing, and personalized engagement, supported by a scalable technology platform and a network of fulfillment centers enabling rapid delivery. The company has expanded into pet healthcare services, including telehealth, pharmacy, and veterinary clinics, and has launched an e-commerce platform for veterinarians. Chewy also operates a subscription-based Autoship program to enhance customer retention. The pet industry is large and growing, with increasing online sales and pet humanization trends supporting demand. Chewy faces strong competition across multiple retail and veterinary channels, competing on price, selection, delivery, and service.

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, including obesity. The company leverages its proprietary Compass platform, which integrates human genetics and variant functionalization to identify and validate novel drug targets. Maze’s pipeline includes two wholly-owned clinical programs: MZE829, an oral inhibitor of APOL1 for APOL1-mediated kidney disease, currently in Phase 2 clinical trials; and MZE782, poised for Phase 2 development targeting PKU and CKD. Additionally, Maze has a partnered program licensed to Shionogi for Pompe disease in Phase 2. The company completed its IPO in February 2025, raising net proceeds of approximately $127.8 million. As of December 31, 2025, Maze reported strong liquidity with cash and short-term investments totaling over $341 million, but also a net loss of $131.1 million for the fiscal year. The company faces competition from established and novel therapies in the kidney disease space and emphasizes intellectual property protection as a key component of its strategy. Recent news highlights include positive Phase 2 topline data for MZE829 and multiple analyst coverage initiations with buy and outperform recommendations.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases, primarily focusing on inherited and age-related degenerative retinal conditions such as retinitis pigmentosa (RP). Its lead product, KIO-301, is a novel photoswitch small molecule designed to restore vision by modulating ion channels in retinal neurons. KIO-301 completed Phase 1b trials with positive safety and efficacy signals and is currently in a Phase 2 trial (ABACUS-2) enrolling patients with ultra-low vision or no light perception. The company has partnered with Théa Open Innovation for global development and commercialization rights outside certain Asian countries and has an option agreement with Senju for Asian territories. Kiora is also developing KIO-104, a potent DHODH inhibitor targeting retinal inflammatory diseases such as diabetic macular edema and posterior non-infectious uveitis, with Phase 2 trials underway. Additionally, KIO-101, a topical formulation of the same active compound as KIO-104, targets ocular manifestations of autoimmune diseases. The company does not currently generate product revenue and finances operations through equity, collaborations, and licensing. As of December 31, 2025, Kiora maintains strong liquidity with cash, short-term investments, and a high current ratio, supporting ongoing clinical development and strategic initiatives.